Echo IQ (ASX: EIQ) Secures A$110 Million Backing to Accelerate US AI Healthcare Expansion

Key Highlights
 

• Echo IQ (ASX: EIQ) raises A$110 million through a strongly supported institutional placement.
• Funding follows FDA clearance, major US partnerships and growing commercial traction.
• Capital will accelerate US sales, product deployment and expansion of its AI cardiovascular platform.

Artificial intelligence is rapidly reshaping healthcare, but turning promising technology into a scalable commercial business often requires significant capital. Echo IQ (ASX: EIQ) believes it has reached that stage.

The healthcare technology company has secured A$110 million through an institutional placement to fund its next phase of growth in the United States, following a series of commercial and regulatory milestones that have strengthened its position in the rapidly expanding AI-driven cardiovascular diagnostics market.

Unlike many early-stage capital raisings that primarily extend a company’s cash runway, Echo IQ’s latest funding comes after the business has already secured important regulatory approvals, established strategic healthcare partnerships and expanded deployments across leading US health systems.

Echo IQ shares traded at $1.59 on Wednesday morning, giving the company a market capitalisation of approximately A$1.05 billion. The stock has been one of the ASX’s strongest performers over the past year, delivering a remarkable 562.50% return while trading within a 52-week range of $0.165 to $1.875.

Source: MarketIndex 

The company said the placement attracted strong support from both existing shareholders and new Australian and international institutional investors, providing independent validation of its commercial strategy.

The funding builds on a series of significant developments over recent months. Echo IQ has already received US Food and Drug Administration (FDA) 510(k) clearance for its EchoSolv Aortic Stenosis (AS) software, while its EchoSolv Heart Failure (HF) product is currently under FDA review.

The company has also strengthened its commercial position through partnerships with Pro Medicus, research collaboration with the Mayo Clinic, and deployments across leading US healthcare providers.

Together, these milestones suggest Echo IQ is moving beyond product development and into broader commercial execution.

Many artificial intelligence healthcare companies spend years obtaining regulatory approvals before facing another challenge: scaling sales teams, integrating software into hospital systems and supporting customers across multiple healthcare networks.

Echo IQ intends to use the new capital to accelerate that rollout while also investing in future products, complementary technologies and potential acquisition opportunities.

Chief Executive Officer Dustin Haines said the placement marks an important stage in the company’s evolution.

“This Placement represents the next step in Echo IQ’s commercial evolution and reflects the strong strategic progress the Company has delivered over recent years.”

He added:

“The support received from both existing and new institutional investors reflects confidence in our strategy, our execution and the significant commercial opportunity ahead.”

Mr Haines said the stronger balance sheet would allow the company to accelerate commercial activity across the United States.

“Following completion of the Placement, we expect to be in a position to accelerate deployment of EchoSolv across the US at a time when customer engagement continues to build.”

Looking beyond its existing products, management also outlined ambitions to develop a broader cardiovascular AI platform.

“Beyond commercial execution, our strengthened balance sheet is expected to enable us to accelerate development of our broader cardiovascular AI platform.”

He added that the company’s immediate priorities remain clear.

“Our focus is firmly on execution which includes growing commercial revenues, expanding our customer base and continuing to establish Echo IQ as a leader in AI-enabled cardiovascular diagnostics.”

The announcement also arrives as healthcare systems increasingly adopt artificial intelligence to assist clinicians with earlier diagnosis, improve workflow efficiency and identify high-risk patients sooner. Cardiovascular disease remains one of the world’s leading causes of death, making AI-powered diagnostic tools one of the fastest-growing areas of medical technology. Industry analysts continue to expect strong long-term demand for AI-assisted clinical decision support as hospitals seek to improve patient outcomes while managing workforce pressures. 

Source: US FDA, American Heart Association and company announcements.

While the capital raise strengthens Echo IQ’s financial position, execution remains the next major test.

The placement will issue approximately 75.9 million new shares, representing around 11.5% of the company’s existing share capital, resulting in shareholder dilution. Commercial success will also depend on expanding hospital adoption, achieving favourable reimbursement pathways and securing FDA clearance for EchoSolv Heart Failure.

For now, however, the latest funding shifts the conversation away from product development and toward commercial delivery.

With regulatory approvals, strategic partnerships and fresh capital now largely in place, the company’s next chapter will be measured by how quickly it can convert growing customer interest into recurring revenue across the world’s largest healthcare market.